본문으로 건너뛰기
cccskills
무료GitHub에 공개

fda-qsr-audit-prep

Prepare for FDA medical device quality audits through six evidence-focused questions. Review complaints, adverse event reports, process validation, manufacturing records, corrective actions, labeling, and inspection history, then organize readiness gaps and three next actions with owners.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

원문원문 설명 보기

/compliance-os:fda-qsr-audit-prep [scope] — FDA 21 CFR 820 (QSR / QMSR) audit 6-question forcing interrogation. Post-Feb 2026 substantially harmonized with ISO 13485. Use before annual internal QSR audit, pre-FDA-inspection readiness, or Form 483 response.

설치 방법 보기

이럴 때 유용합니다

  • Preparing for an annual internal quality audit
  • Reviewing readiness before an FDA inspection
  • Organizing evidence for a Form 483 response
  • Cross-checking audit evidence against ISO 13485

포함된 파일(1)

  • SKILL.md6.4 KB

SKILL.md(원문)

설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.

/compliance-os:fda-qsr-audit-prep — FDA QSR Forcing Questions

Command: /compliance-os:fda-qsr-audit-prep <scope>

The FDA QSR auditor pressure-tests any US medical-device QSR work. Six questions before any internal audit, FDA inspection, Form 483 response, or recall decision.

When to Run

  • Before annual internal QSR audit
  • Before pre-FDA-inspection readiness review (any device commercially distributed in US)
  • After receiving Form 483 observations
  • After Warning Letter receipt
  • After MDR-reportable event
  • Before recall decision (voluntary vs FDA-initiated)
  • Before submitting 510(k) / PMA (where QSR posture affects approval timeline)

The Six QSR Questions

1. Show me the complaint files from the last quarter — and the corresponding MDR reports.

21 CFR 820.198 + 21 CFR 803 — most-cited FDA inspection area.

  • Complaint log complete: who / what / when / device / batch
  • Investigation closure within reasonable timeline
  • MDR-reporting decision tree applied: death OR serious injury OR malfunction-that-could-cause = MDR
  • 30-day timeline for most MDR reports; 5 days for certain serious events
  • Complaint trending input to management review

2. When was process validation (IQ/OQ/PQ) last revalidated per 21 CFR 820.75?

Cross-walks ISO 13485 Clause 7.5.6 (substantially harmonized post-Feb 2026).

  • Initial validation at process introduction
  • Revalidation triggers: process / equipment / material change OR periodic schedule
  • Statistical techniques per 21 CFR 820.250 where applicable
  • Cross-check with cs-cqm-iso13485 for ISO 13485 alignment

3. Show me the DHRs for products commercially distributed in last 2 years.

21 CFR 820.180 — 2-year retention from commercial distribution; check sampling for completeness.

  • Device History Record (DHR) for each unit/lot/batch
  • Must include: dates of manufacture, quantity manufactured, quantity released, acceptance records, primary identification label, device identification, control number
  • Sample stratified by product class
  • Verify DHR closeness to DHF (design history file)

4. Show me CAPAs from the last 6 months with effectiveness verification.

21 CFR 820.100 = ISO 13485 8.5.2 substantially harmonized.

  • Root cause analysis depth (5 Why minimum)
  • Effectiveness verification = measurable evidence, not "we updated the procedure"
  • Containment / correction / corrective action distinction documented
  • Closure approval by appropriate authority
  • Aging CAPAs > 90 days flagged

5. Show me labeling (21 CFR 801) review for the most recent product launch.

FDA-specific overlay not in ISO 13485.

  • Labeling per 21 CFR 801 requirements
  • For specific device types: also 21 CFR 800 series sectoral overlays
  • UDI (Unique Device Identification) per 21 CFR 830
  • Promotional materials reviewed for accuracy + non-misleading

6. If a Form 483 was issued in the last 3 years, show me the closure status.

Form 483 = FDA observation; not equivalent to ISO nonconformity.

  • Response within 15 working days
  • Each observation has documented corrective + preventive action with timeline
  • Effectiveness verification evidence
  • For Warning Letters: separate response track + potentially FDA meeting

Workflow

# 1. QSR compliance posture
python ${CLAUDE_PLUGIN_ROOT}/vendor/ra-qm-team/fda-consultant-specialist/scripts/qsr_compliance_checker.py compliance_state.json

# 2. FDA submission tracking (510(k) / PMA / IDE)
python ${CLAUDE_PLUGIN_ROOT}/vendor/ra-qm-team/fda-consultant-specialist/scripts/fda_submission_tracker.py submissions.json

# 3. HIPAA overlap (if connected device handles PHI)
python ${CLAUDE_PLUGIN_ROOT}/vendor/ra-qm-team/fda-consultant-specialist/scripts/hipaa_risk_assessment.py phi_inventory.json

# 4. Mock FDA inspection
python ../../skills/compliance-os/scripts/audit_simulator.py fda_qsr_scope.json

Output Format

# FDA QSR Audit Prep: <scope>
**Date:** YYYY-MM-DD

## The Decision Being Made
[programme-plan | inspection-readiness | 483-response | MDR-decision | recall]

## Complaint + MDR Posture
- Complaints last quarter: N
- MDR-reportable events: M
- MDR reports filed within timeline: % (target 100%)
- Complaint trending review at management level: yes/no

## Process Validation Status (21 CFR 820.75)
- Validations on schedule: %
- Stale validations: <list>
- Statistical techniques applied: yes/no per process

## DHR Completeness (21 CFR 820.180)
- DHRs sampled: N
- Completeness rate: %
- 2-year retention compliant: yes/no
- Stratified by product class: yes/no

## CAPA Health (21 CFR 820.100)
- CAPAs sampled: N
- Root cause analysis depth: adequate/inadequate
- Effectiveness verification: complete/incomplete
- Aging CAPAs > 90 days: N

## Labeling (21 CFR 801)
- Recent products reviewed: <list>
- Labeling accurate + non-misleading: yes/no
- UDI compliance per 21 CFR 830: yes/no

## Form 483 / Warning Letter History
- Form 483s last 3 years: N (each: closed/in-progress)
- Warning Letters last 5 years: N (each: closed/in-progress)
- Pattern across observations: <thematic>

## ISO 13485 Cross-Walk (post-Feb 2026 harmonization)
- ISO 13485 audit findings: <link to cs-cqm-iso13485 output>
- FDA-specific overlays remaining: labeling + complaint handling + MDR reporting + recall procedures
- Cross-framework reuse: % of evidence shared

## Verdict
🟢 INSPECTION-READY | 🟡 GAPS-IDENTIFIED | 🔴 NOT-READY

## Top 3 Actions
[3 concrete next steps with owner + FDA-cited timeline (15 days / 30 days / etc.)]

## Outside Counsel Required
[For Warning Letter response, recall decisions, or 510(k) / PMA strategy disputes]

Routing

  • /compliance-os:compliance-readiness — for multi-framework view
  • /compliance-os:iso13485-audit-prep — for ISO 13485 cross-walk pair (substantially harmonized)
  • /compliance-os:gdpr-audit-prep — if connected device handles personal data
  • /c-level-agents:gc-review — for Warning Letter response coordination

Related


Version: 1.0.0

리뷰

아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.

댓글

로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.

아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.

보내면 바로 공개됩니다. 이메일 주소나 전화번호 같은 개인 정보는 쓰지 마세요. URL은 2개까지입니다.

0 / 1,000자

이 양식은 reCAPTCHA로 보호되며 Google 개인정보처리방침 및 서비스 약관이 적용됩니다.

같은 저장소의 스킬

Audit web applications for accessibility issues against WCAG 2.2 Level A and AA, the web accessibility standards. Get framework-specific code fixes, contrast checks, verification steps, and reports, with options for automated checks in development pipelines.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

  • Audit a web application before release
  • Fix contrast and keyboard navigation issues
  • Prepare accessibility reports for stakeholders
alirezarezvani/claude-skills2.9만2026년 10월 21일 업데이트

Plan A/B tests that compare page variations, from headlines to pricing layouts. Define a hypothesis, choose success metrics, calculate sample size and duration, and prepare launch checks and results reports to support decisions.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

  • Comparing landing page headlines
  • Testing signup button changes
  • Planning pricing page experiments
alirezarezvani/claude-skills2.9만2026년 10월 21일 업데이트

Create paid ad headlines and body copy tailored to each platform's character limits. Use existing performance data to develop variations, explore new messaging angles, and check copy for length, quality, and potential rejection risks.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

  • Creating Google RSA headlines
  • Writing Meta and LinkedIn ad copy
  • Developing variations of successful ads
alirezarezvani/claude-skills2.9만2026년 10월 21일 업데이트

Review code changes from three critical perspectives: production failures, maintainability, and security. Get a consolidated report that ranks findings by severity and provides merge guidance, helping examine assumptions that an ordinary self-review may overlook.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

  • Reviewing a pull request before merging
  • Getting a second opinion on AI-written code
  • Checking authentication or data access code
alirezarezvani/claude-skills2.9만2026년 10월 21일 업데이트

aeo

무료

Audit and improve content intended for citation in AI answers. Review evidence, author information, and structure, generate revised content and structured metadata, and keep a local record of observed citations across AI services.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

  • Audit existing articles for evidence and credibility gaps
  • Revise article structure and references for AI answers
  • Record citations observed across AI services
alirezarezvani/claude-skills2.9만2026년 10월 21일 업데이트

Create signed records for consequential agent actions such as deployments, deletions, and payments. Decide which actions need evidence, record the agent, action, target, and policy, then verify the resulting certificate offline to detect later changes.

한국어 요약은 준비 중입니다. 영어 요약을 표시하고 있습니다.

  • Creating signed records for production deployments
  • Preserving evidence of deletions and payments
  • Recording access grants for later review
alirezarezvani/claude-skills2.9만2026년 10월 21일 업데이트

alirezarezvani의 스킬 모두 보기

이 스킬의 문제 신고